BioSpace News Archive

Conference call to discuss financial and operational results scheduled for Friday, May 8 at 8:30 a.m. U.S. Eastern Time

NURTEC™ ODT (rimegepant) received FDA-approval for acute treatment of migraine on February 27, 2020 and Biohaven reports net revenues of $1.2M in March 2020 after launch in U.S. Pharmacies

Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compared to $1.6 billion at December 31, 2019.

Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported financial and operating results for the first quarter ended March 31, 2020.

NantHealth, Inc., a next-generation, evidence-based, personalized healthcare company, reported financial results for its first quarter ended March 31, 2020.

Intersect ENT, Inc., announced that management will participate in a virtual fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference.

Tricida, Inc., a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease, announced financial results for the three months ended March 31, 2020 and provided an update on key initiatives.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, reported financial results for the quarter ended March 31, 2020 and provided a corporate update.